Oklahoma Medical Research Foundation

Summary

Oklahoma Medical Research Foundation is a medical facility located in Oklahoma City, Oklahoma. This center is recognized for care of Systemic Lupus Erythematosus, Lupus, Multiple Sclerosis, Coronary Artery Disease, Rheumatoid Arthritis and other specialties. Oklahoma Medical Research Foundation is involved with conducting 154 clinical trials across 125 conditions. There are 6 research doctors associated with this hospital, such as Gabriel Pardo, Cristina Arriens, MD, MSCS, Judith A. James, MD, PhD, and Christina Arriens, MD.

Top PIs

Clinical Trials running at Oklahoma Medical Research Foundation

Systemic Lupus Erythematosus

Lupus

Multiple Sclerosis

Lupus Nephritis

Critical Illness

Muscle Weakness

Antiphospholipid Syndrome

Sarcopenia

Relapse

Acquired Weakness

Shingles Vaccine

for Lupus

This randomized, double-blind, placebo-controlled, non-inferiority crossover study will evaluate the Herpes Zoster Sunbit (HZ/su) vaccine in SLE patients in order to evaluate safety and immunogenicity in patients with variable baseline clinical activities, ages and immunosuppressant exposures. The investigators hypothesize that HZ/su administration will be non-inferior to placebo with respect to the risk of moderate or severe SLE flare(s) occurring within 24 weeks of receiving the first dose of the assigned treatment. In addition, the investigators hypothesize that immunogenicity of the vaccine in SLE patients will be at least 50% of levels observed in healthy subjects from prior large clinical trials.

Recruiting

2 awards

Phase 4

Pregnancy Outcomes

for Lupus and Antiphospholipid Syndrome

The PROMISSE Study is an observational study of 700 pregnant patients, enrolled at nine major clinical centers. The purpose of the study is 1) to determine whether certain proteins (called complement split products) that can injure healthy organs can be used to predict poor pregnancy outcome in patients with systemic lupus erythematosus (SLE) and anti-phospholipid syndrome (APS), and/or 2) to determine whether elevated levels of circulating antiangiogenic factors predict pregnancy complications in patients with aPL antibodies and/or SLE.

Recruiting

1 award

N/A

10 criteria

Stopping Hydroxychloroquine

for Lupus

This trial is testing if older lupus patients can safely stop taking Hydroxychloroquine, a drug that reduces lupus symptoms but can harm the eyes over time. The study focuses on patients aged 60 and above who have stable disease. Researchers will monitor these patients for an extended period to see if their condition remains stable without the drug.

Recruiting

1 award

Phase 3

1 criteria